IP Library › Granted Patent US 11,986,541
Granted Patent B2
US 11,986,541 · App. 18/232,013 · Granted May 21, 2024

Method of preventing the development of melanoma

Inventors: Peter Novak (Sunny Isles Beach, FL); Max Temnik (Miami, FL); Oleksandr Balakin (Dnepropetrovsk, UA)
Assignee: Vector Vitale IP LLC
A61K51/0476A61K31/164A61K33/30A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,986,541
App. No.
18/232,013
Granted
May 21, 2024
Kind
B2
Abstract

A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64 Zn e (Asp) 2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64 Zn e (Asp) 2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Claims (5)

1. A method of reducing melanoma tumor growth of a primary melanoma in a patient in need thereof, comprising suppressing tumor growth of the primary melanoma by administering a composition comprising a therapeutically effective amount of 64 Zn e (Asp) 2 to said patient wherein from 0.2 ug/kg to 2000 mg/kg patient weight/day of 64 Zn e (Asp) 2 is administered to the patient and; wherein the 64 Zn e (Asp) 2 is at least 90% 64 Zn and is administered intratumorally to the primary melanoma of said patient.

2. The method of claim 1 , wherein the composition is an aqueous solution.

3. The method of claim 1 , wherein the composition is administered once a day.

4. The method of claim 1 , wherein the composition is administered more than once a day.

5. The method of claim 1 , wherein the composition further comprises deuterium-depleted water as a solvent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: BALAKIN, OLEKSANDR
To: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
Reel/Frame 068674/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 068674/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: TEMNIK, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 067823/0555 →
Continuity (3)
Continuation 17969297 · Oct 19, 2022
Continuation 16692584 · Nov 22, 2019
Related Publication 20230381347A1 · Nov 30, 2023
Cited By (1)
US 12,734,240